Claret Asset Management Reduces Stake in Exelixis by 40.9%

Claret Asset Management Corp has significantly reduced its stake in Exelixis, Inc. (NASDAQ: EXEL), decreasing its holdings by 40.9% during the second quarter of 2023. The firm disclosed its decision in a recent filing with the Securities and Exchange Commission (SEC), revealing that it now owns 5,326 shares of the biotechnology company after selling 3,692 shares during this period. As of the end of the last quarter, Claret’s investment in Exelixis was valued at approximately $235,000.

Several institutional investors have also made significant adjustments to their positions in Exelixis. Hemington Wealth Management increased its holdings by 211.3% in the first quarter, now owning 769 shares worth about $28,000 after acquiring an additional 522 shares. Similarly, Byrne Asset Management LLC raised its stake by 129.0% in the second quarter, now holding 710 shares valued at $31,000 following a purchase of 400 shares.

Family Legacy Financial Solutions LLC entered the market by acquiring a new stake in Exelixis worth approximately $33,000. Costello Asset Management INC also established a new position valued at about $39,000 in the first quarter. Notably, Harbour Investments Inc. boosted its holdings by an impressive 900.0%, acquiring 1,100 shares now valued at $41,000.

As a result of these transactions, institutional investors and hedge funds now collectively own 85.27% of Exelixis stock.

Insider Transactions and Stock Performance

In other news related to Exelixis, Director Stelios Papadopoulos sold 100,000 shares on November 12, generating a total of $4,355,000 at an average price of $43.55. After this transaction, Papadopoulos holds 1,189,228 shares, valued at around $51,790,879.40, marking a 7.76% decrease in his ownership.

Executive Vice President Dana Aftab also sold 48,383 shares on November 11, realizing $2,056,277.50 at an average price of $42.50. Following this sale, Aftab retains 664,778 shares, valued at approximately $28,253,065, reflecting a 6.78% decrease in position. Over the past ninety days, insiders have sold a total of 245,235 shares worth $10,490,600, with insiders currently holding 2.82% of the company’s stock.

Recent Financial Performance

Exelixis stock opened at $43.43 on November 4, 2023, showing a slight decline of 1.7% that day. The company has a 50-day moving average price of $40.32 and a 200-day moving average price of $40.86. Over the last year, Exelixis has experienced a 12-month low of $31.90 and a high of $49.62, with a market capitalization of $11.64 billion.

In its latest quarterly earnings report, Exelixis posted earnings of $0.78 per share, surpassing the consensus estimate of $0.68 by $0.10. The company reported revenues of $597.76 million, exceeding analysts’ expectations of $590.04 million. Year-over-year, revenue increased by 10.8%, with a net margin of 27.01% and a return on equity of 27.47%. For the current year, analysts anticipate Exelixis will report an EPS of $2.04.

Exelixis, Inc. specializes in developing innovative therapies for challenging cancers, offering products such as CABOMETYX for renal cell carcinoma and COMETRIQ for medullary thyroid cancer. For more updates on Exelixis and related market activity, please visit reliable financial news platforms.